Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 8/20 | 0.56 |
| ▸ | GABBR1 | Q9UBS5 | 8/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL350645 | 0.82 | GABBR2 (0.38) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL351660 | 0.82 | GABBR2 (0.57) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL350711 | 0.81 | GABBR2 (0.56) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL350431 | 0.81 | CES2 (0.39) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL350238 | 0.78 | ALDH1A1 (0.47) | CYP1A2CYP3A4CYP2D6CYP2C19MEN1 | |
| SCHEMBL11085032 | 0.78 | GABBR2 (0.62) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL5230376 | 0.75 | GABBR2 (0.59) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL351702 | 0.73 | GABBR2 (0.70) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL351502 | 0.73 | GABBR2 (0.70) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL5321547 | 0.72 | GABBR2 (0.56) | GABBR2GABBR1LMNACYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016021-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | XENOPORT, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009646-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | XENOPORT, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016021-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | GABBR2, GABBR1, GABRB1 | GABBR2 1/4885GABBR1 2/4885LMNA 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.